DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

NCT03361098 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Obesity

Interventions

DRUG: Dapagliflozin 10mg
DRUG: Exenatide
OTHER: placebo exenatide
OTHER: placebo dapagliflozin

Sponsor

Amsterdam UMC, location VUmc

Collaborators

[object Object]